Jeffrey Cole, MD
Cardiovascular Disease · Baltimore, MDNPI 1548263908
Payments from drug & device makers
Across 257 payments — averaging $18,818 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$4.6M
- Ionis Pharmaceuticals, Inc.$85K
- Amgen$62K
- Novartis$21K
- Genentech, Inc.$11K
- Esperion Therapeutics, Inc.$8K
- plus $2K from 24 others
Across 13 payments — averaging $6493.93 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$84K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 40 | $4,647,139 |
| Ionis Pharmaceuticals, Inc. | 11 | $84,787 |
| Amgen | 19 | $61,826 |
| Novartis | 39 | $21,109 |
| Genentech, Inc. | 2 | $11,100 |
| Esperion Therapeutics, Inc. | 18 | $8,498 |
| Boehringer Ingelheim | 14 | $265 |
| Johnson & Johnson | 18 | $155 |
| Pfizer | 20 | $153 |
| Novo Nordisk | 7 | $134 |
| AstraZeneca | 8 | $111 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 13 | $97 |
| Amarin Pharma, Inc. | 5 | $83 |
| Actelion Pharmaceuticals US, Inc. | 5 | $81 |
| Regeneron Healthcare Solutions, Inc. | 4 | $74 |
| Sanofi-aventis U.S. LLC | 4 | $73 |
| Kestra Medical Technology Services, Inc. | 1 | $63 |
| Gilead | 5 | $62 |
| Boston Scientific | 2 | $47 |
| E.r. Squibb & Sons, L.L.C. | 3 | $40 |
| Merck | 2 | $33 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $29 |
| Vivaquant Inc, Dba Rhythm Express | 5 | $26 |
| Arbor Pharmaceuticals, Inc. | 2 | $25 |
| Bayer | 2 | $25 |
| Abbott | 1 | $25 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $24 |
| Akcea Therapeutics, Inc. | 1 | $16 |
| Philips North America LLC | 1 | $16 |
| Medtronic | 1 | $11 |
How this compares
$4,836,129 in reported general payments places this provider in the 95th percentile of 507 cardiovascular disease providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other cardiovascular disease in Baltimore
- Christopher DefilippiBaltimore$9.2M
- Thorsten LeuckerBaltimore$7.1M
- Joao LimaBaltimore$5.6M
- Carlos InceBaltimore$3M
- Paul GurbelBaltimore$2.6M
- Navin KapurBaltimore$1.8M
- Robert WeissBaltimore$1.4M
- Stephen GottliebBaltimore$1.4M
- Jesse DoranBaltimore$1.1M
- Armin Arbab-ZadehBaltimore$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.